Last Price$272.70.1%
Market Cap$19.4B
LTM Operating Cash Flow margin
22.6%
5Y avg
8.3%
Medical - Devices industry
median
(21.6%)
Stock quality & Intrinsic value
8/10
(0.5%) overvalued
Insulet Corporation Operating Cash Flow margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow margin | 0.0% | (40,642.0%) | (868.7%) | (376.7%) | (229.1%) | (74.7%) | (36.7%) | (16.7%) | (13.7%) | 1.4% | 3.1% | (4.8%) | 4.3% | 8.9% | 6.4% | 13.3% | 9.3% | (6.2%) | 9.1% | 8.6% |
Overvalued or undervalued?
Check the intrinsic value for PODD
and see if it's the right time to invest.
Insulet Corporation (PODD) Operating Cash Flow margin comparison analysis
General
LTM Operating Cash Flow margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Insulet CorporationPODD
22.6%
30.0%
4,364.6%
12.2%
Median Peer Set
19.6%
4.1%
72.0%
12.4%
Zimmer Biomet Holdings, Inc.ZBH
26.5%
6.5%
253.2%
13.8%
Medtronic plcMDT
22.0%
3.6%
(2.1%)
11.4%
STERIS plcSTE
21.2%
3.6%
257.9%
7.4%
Boston Scientific CorporationBSX
20.5%
17.6%
16.7%
11.1%
Abbott LaboratoriesABT
20.4%
4.6%
134.5%
31.9%
Stryker CorporationSYK
18.8%
10.2%
(5.8%)
13.2%
Align Technology, Inc.ALGN
18.5%
3.4%
26.0%
11.5%
DexCom, Inc.DXCM
17.1%
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
13.7%
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V.PHG
1.5%
(0.8%)
118.1%
(3.9%)
PODD key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.1 0.0% | 3.7 7,226.0% | 13.4 265.1% | 36.1 169.7% | 66.0 83.1% | 97.0 46.8% | 152.3 57.0% | 211.4 38.8% | 247.1 16.9% | 288.7 16.9% | 263.9 (8.6%) | 367.0 39.1% | 463.8 26.4% | 563.8 21.6% | 738.2 30.9% | 904.4 22.5% | 1,098.8 21.5% | 1,305.3 18.8% | 1,697.1 30.0% |
| Cost of Goods Sold (COGS) | 0.0 | 1.5 | 15.7 | 25.7 | 40.6 | 47.7 | 53.2 | 85.5 | 119.0 | 134.7 | 145.4 | 130.6 | 155.9 | 186.6 | 193.7 | 257.9 | 322.1 | 346.7 | 499.7 | 537.2 |
% margin | 0.0 0.0% | (1.5) (2,960.0%) | (12.0) (327.5%) | (12.4) (92.4%) | (4.6) (12.7%) | 18.3 27.7% | 43.7 45.1% | 66.7 43.8% | 92.3 43.7% | 112.4 45.5% | 143.3 49.6% | 133.3 50.5% | 211.1 57.5% | 277.2 59.8% | 370.2 65.7% | 480.3 65.1% | 582.3 64.4% | 752.1 68.4% | 805.6 61.7% | 1,159.9 68.3% |
| Operating Expenses | 14.2 | 20.0 | 22.6 | 41.5 | 84.8 | 77.7 | 77.9 | 109.2 | 128.3 | 141.5 | 155.6 | 182.0 | 221.8 | 284.6 | 342.7 | 430.3 | 530.8 | 626.1 | 768.0 | 939.9 |
| Research & Development Expenses (R&D) | 9.0 | 10.8 | 8.1 | 10.4 | 13.1 | 13.2 | 16.6 | 21.9 | 24.4 | 21.8 | 27.9 | 43.2 | 55.7 | 74.5 | 88.6 | 129.7 | 146.8 | 160.1 | 180.2 | 205.0 |
| Selling, General & Administrative Expenses (SG&A) | 5.1 | 9.3 | 14.6 | 30.1 | 63.5 | 64.4 | 61.4 | 87.3 | 103.9 | 119.8 | 127.7 | 138.8 | 166.1 | 210.1 | 254.1 | 300.6 | 384.0 | 466.0 | 587.8 | 734.9 |
% margin | (14.2) 0.0% | (21.5) (43,010.0%) | (34.6) (945.8%) | (53.8) (402.6%) | (89.3) (247.8%) | (59.4) (89.9%) | (38.6) (39.8%) | (42.5) (27.9%) | (36.0) (17.0%) | (29.1) (11.8%) | (12.3) (4.3%) | (48.7) (18.5%) | (10.7) (2.9%) | (7.4) (1.6%) | 27.4 4.9% | 22.1 3.0% | (0.6) (0.1%) | 66.7 6.1% | (26.7) (2.0%) | 220.0 13.0% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 1.8 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.8 | 2.6 | 6.7 | 7.8 | 3.0 | 0.5 | 9.8 | 28.6 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 7.2 | 20.2 | 22.7 | 14.7 | 15.8 | 17.2 | 14.7 | 12.7 | 14.4 | 19.2 | 22.2 | 26.8 | 45.1 | 61.2 | 26.7 | 36.2 |
| Pre-tax Income | 0.0 | 0.0 | (35.5) | (53.5) | (92.8) | (79.5) | (61.2) | (57.0) | (51.7) | (44.9) | (51.4) | (61.4) | (26.8) | (26.6) | 5.2 | 14.5 | 9.7 | 20.5 | 9.8 | 214.6 |
% effective tax rate | (0.3) 0.0% | 0.1 0.0% | 1.3 (3.7%) | (0.3) 0.6% | 3.4 (3.7%) | (5.2) 6.6% | 21.9 (35.8%) | 0.1 (0.2%) | 0.2 (0.4%) | 0.1 (0.2%) | 0.1 (0.3%) | 0.2 (0.3%) | 0.4 (1.5%) | 0.3 (1.0%) | 1.9 37.0% | 2.9 20.0% | 2.9 29.9% | 3.7 18.0% | 5.2 53.1% | 8.3 3.9% |
% margin | (13.8) 0.0% | (21.6) (43,272.0%) | (36.0) (981.4%) | (53.5) (400.4%) | (92.8) (257.3%) | (79.5) (120.5%) | (61.2) (63.1%) | (57.2) (37.5%) | (51.9) (24.5%) | (45.0) (18.2%) | (51.5) (17.8%) | (73.5) (27.9%) | (28.9) (7.9%) | (26.8) (5.8%) | 3.3 0.6% | 11.6 1.6% | 6.8 0.8% | 16.8 1.5% | 4.6 0.4% | 206.3 12.2% |
| EPS | (47.64) | (70.95) | (99.10) | (3.21) | (3.36) | (2.68) | (1.54) | (1.22) | (1.08) | (0.83) | (0.93) | (1.29) | (0.51) | (0.46) | 0.06 | 0.19 | 0.11 | 0.25 | 0.07 | 2.96 |
| Diluted EPS | (47.64) | (70.95) | (39.19) | (3.21) | (3.36) | (2.68) | (1.54) | (1.22) | (1.08) | (0.83) | (0.93) | (1.29) | (0.50) | (0.46) | 0.05 | 0.19 | 0.10 | 0.25 | 0.07 | 2.80 |
% margin | (13.5) 0.0% | (20.3) (40,538.0%) | (32.0) (873.7%) | (48.9) (365.9%) | (81.2) (225.1%) | (53.9) (81.6%) | (33.4) (34.4%) | (35.8) (23.5%) | (24.8) (11.7%) | (16.2) (6.5%) | (24.4) (8.5%) | (36.3) (13.7%) | 1.3 0.3% | 6.5 1.4% | 49.8 8.8% | 77.0 10.4% | 110.3 12.2% | 139.6 12.7% | 109.5 8.4% | 323.6 19.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Insulet Corporation's Operating Cash Flow margin?
As of today, Microsoft Corp's last 12-month Operating Cash Flow margin is 22.6%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Operating Cash Flow margin for Insulet Corporation have been 7.1% over the past three years, and 8.7% over the past five years.
2) Is Insulet Corporation's Operating Cash Flow margin Good?
As of today, Insulet Corporation's Operating Cash Flow margin is 22.6%, which is higher than industry median of (21.6%). It indicates that Insulet Corporation's Operating Cash Flow margin is Good.